DCPH News and Press, Deciphera Pharmaceuticals Inc. From 05/08/23

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JM...

2023-05-07 04:58:09 ET Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Conference Call May 03, 2023, 08:00 AM ET Company Participants Jen Larson - Senior Vice President-Finance and Investor Relations Steve Hoerter - President and Chief Executive Officer M...

2023-05-03 07:25:22 ET Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q1 GAAP EPS of -$0.60 misses by $0.01 . Revenue of $33.45M (+14.6% Y/Y) misses by $2.05M . For further details see: Deciphera Pharmaceuticals GAAP EPS of -$0.60 misses by $0....

– First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in the MOTION Pivotal Phase 3 Study of Vimseltinib; Top-line Results Expected in the Fourth...

2023-05-02 13:12:36 ET Deciphera Pharmaceuticals ( NASDAQ: DCPH ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.60 (+25.0% Y/Y) and the consensus Revenue Estimate is $35.5M (+21.6% Y/Y). Over t...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3,...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the St...

2023-03-29 11:49:16 ET The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshow

2023-03-25 08:00:00 ET Summary Last year, Deciphera Pharmaceuticals, Inc. was almost destroyed by a trial failure. This year, Deciphera Pharmaceuticals has demonstrated huge benefit in a subpopulation, and also progressed the rest of its pipeline. The cash position is decent, ...

2023-03-18 05:21:53 ET Summary Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in treating various types of cancer. The company has compl...